Medicinal chemistry of sirtuin inhibitors

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

As members of Class III histone deacetylases (HDACs), sirtuins use stoichiometric nicotinamide adenine dinucleotide (NAD+) to remove the acetyl group from N-acetyl-lysines of histones or non-histone proteins. Sirtuins have been implicated in metabolic diseases, cancer, and neurodegenerative diseases, constituting a promising target for drug discovery. While the early sirtuin inhibitors mimicked NAD+ or substrate peptides, high-throughput and in silico screenings have identified a wide range of core structures, many of which have been subjected to medicinal chemistry efforts. This review outlines inhibitor chemotypes, and their chemical modifications and biological evaluations, highlighting strategies to enhance inhibitory activity and selectivity among isoforms.

Original languageEnglish (US)
Pages (from-to)1936-1946
Number of pages11
JournalCurrent medicinal chemistry
Volume18
Issue number13
DOIs
StatePublished - May 1 2011

Keywords

  • Cancer therapy
  • Drug design
  • Drug discovery
  • High-throughput screening
  • Histone deacetylase
  • NAD
  • Phenotypic screening
  • Sirtuin
  • Sirtuin inhibitor
  • Virtual screening

Fingerprint

Dive into the research topics of 'Medicinal chemistry of sirtuin inhibitors'. Together they form a unique fingerprint.

Cite this